Last reviewed · How we verify
Tdcp
At a glance
| Generic name | Tdcp |
|---|---|
| Sponsor | CanSino Biologics Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) (PHASE1)
- A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) (PHASE2, PHASE3)
- Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan (PHASE3)
- Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis (PHASE2)
- Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age
- Immunogenicity and Safety of Adacel Polio Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tdcp CI brief — competitive landscape report
- Tdcp updates RSS · CI watch RSS
- CanSino Biologics Inc. portfolio CI